BIOGEN INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $3.7b $2.5b $4.4b $5.9b $4.0b $1.6b $3.0b $1.2b $1.6b $1.3b
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $3.7b $2.7b $4.5b $5.9b $4.1b $1.7b $3.0b $1.2b $1.6b $1.3b
Net Income (Loss) Attributable to Noncontrolling Interest ($7.1m) $131.0m $43.3m $0 $59.9m $171.5m ($85.3m) $400k $0 $0
Depreciation, Depletion and Amortization $682.7m $1.1b $1.0b $680.6m $457.2m $487.7m $518.4m $494.8m $673.2m $779.9m
Depreciation $309.3m $266.3m $269.4m $190.6m $201.9m $235.3m $272.4m $254.2m $286.7m $272.8m
Amortization of Intangible Assets $385.6m $814.7m $381.2m $274.0m $255.1m $252.0m $246.3m $240.6m $386.5m $507.1m
Deferred Income Tax Expense (Benefit) ($175.0m) $91.7m $108.3m $67.1m $149.0m ($426.8m) ($168.6m) ($305.8m) ($158.1m) $361.6m
Share-based Payment Arrangement, Noncash Expense $154.8m $128.0m $157.5m $182.3m $198.3m $238.6m $254.1m $264.2m $291.2m $290.8m
Payment, Tax Withholding, Share-based Payment Arrangement $5.3m $2.1m $700k $1.9m $44.3m $31.3m $10.0m
Share-based Payment Arrangement, Expense $169.4m $138.1m $168.7m $191.2m ($204.5m) ($246.6m) ($263.5m) ($274.4m) ($301.5m)
Impairment of Intangible Assets (Excluding Goodwill) $366.1m $215.9m $209.7m $629.3m $119.6m $0 $60.2m $7.9m
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $215.9m $209.7m $119.6m $0 $40.0m $7.9m
Operating Lease, Impairment Loss $52.9m
Equity Method Investment, Realized Gain (Loss) on Disposal $1.5b $0 $0
Gain (Loss) on Disposition of Intangible Assets $88.6m $0
Gain (Loss) on Disposition of Property Plant Equipment ($616.1m) ($867.4m) ($770.6m) ($514.5m) ($424.8m) ($258.1m) $503.7m $0 $0 ($153.8m)
Income (Loss) from Equity Method Investments $0 $0 $0 ($79.4m) $3.3m $34.9m $2.6m $0 $0
Income Tax Expense (Benefit) $1.2b $2.5b $1.4b $1.2b $992.3m $52.5m $632.8m $135.3m $273.8m $263.6m
Other Nonoperating Income (Expense) ($217.4m) ($13.1m) ($10.5m) ($47.0m) $2.9m ($5.6m) $10.1m $3.5m $29.6m ($24.7m)
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $241.4m $435.6m $205.2m ($68.8m) ($2.8m) ($324.8m) $203.4m ($61.3m) ($222.3m) ($102.7m)
Increase (Decrease) in Inventories $165.6m $94.5m $52.1m $19.2m $316.3m $462.4m $320.2m $130.9m $273.8m $64.7m
Proceeds from Stock Options Exercised $700k $800k $400k $700k
Equity Securities, FV-NI, Gain (Loss) $200.1m $693.9m ($821.1m) $264.7m $275.2m $100.4m $19.7m
Equity Securities, FV-NI, Realized Gain (Loss) ($50.0m) $12.1m $10.3m $0 $5.2m ($2.0m) $1.5m
Equity Securities, FV-NI, Unrealized Gain (Loss) $150.1m $681.8m ($831.4m) $264.7m $270.0m $102.4m $18.2m
Foreign Currency Transaction Gain (Loss), before Tax ($9.8m) $6.3m ($9.9m) ($7.0m) ($10.7m) ($22.4m) $35.5m $50.4m $30.9m $28.6m
Goodwill $3.7b $4.6b $5.7b $5.8b $5.8b $5.8b $5.7b $6.2b $6.5b $6.5b
Inventory Write-down $48.2m $76.9m $41.9m $52.2m $26.6m $167.6m $336.2m $124.4m $101.9m $29.2m
Investment Income, Interest $63.4m $78.5m $112.5m $120.0m $42.0m $11.0m $89.3m $276.5m $67.6m $125.0m
Nonoperating Income (Expense) ($215.4m) $11.0m $83.3m $497.4m ($1.1b) $108.2m ($315.5m) ($343.6m) ($305.6m)
Pension Cost (Reversal of Cost) $17.5m $16.8m
Realized Investment Gains (Losses) $12.1m
Restructuring Costs $10.3m
Unrealized Gain (Loss) on Investments ($124.8m) ($147.3m) ($681.8m) $826.8m $265.9m $277.1m $101.4m $19.3m
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax $4.0m ($31.5m) ($41.8m) $115.0m
Net Cash Provided by (Used in) Operating Activities $4.5b $4.6b $6.2b $7.1b $4.2b $3.6b $1.4b $1.5b $2.9b $2.2b
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $616.1m $867.4m $770.6m $514.5m $424.8m $258.1m $240.3m $277.0m $153.7m $153.8m
Payments to Acquire Businesses, Net of Cash Acquired $0 $0 $744.4m $6.9b $1.1b
Gain (Loss) on Sale of Investments $6.0m ($36.3m) $119.5m $204.7m $685.7m ($824.9m) $277.3m $291.2m $100.4m $19.7m
Payments for (Proceeds from) Other Investing Activities $22.8m $11.0m ($400k) ($27.0m) $26.9m ($12.9m) ($24.4m) $11.3m $4.7m ($42.9m)
Net Cash Provided by (Used in) Investing Activities ($2.5b) ($3.0b) ($2.0b) $470.5m ($608.6m) ($563.7m) $1.6b ($4.1b) ($799.2m) ($1.4b)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $3.0b $0 $0 $997.2m $0 $1.7b
Repayments of Long-term Debt $1.8b
Payments for Repurchase of Common Stock $1.0b $1.4b $4.4b $5.9b $6.7b $1.8b $750.0m $0 $0
Proceeds from (Payments to) Noncontrolling Interests ($94.4m) $12.4m $12.3m $0 $0
Proceeds from (Payments for) Other Financing Activities ($2.8m) ($8.6m) ($19.5m) $3.6m $14.6m ($21.1m) ($5.6m) ($6.0m) ($2.2m) $5.0m
Net Cash Provided by (Used in) Financing Activities ($987.8m) ($2.4b) ($4.5b) ($5.9b) ($5.3b) ($2.1b) ($1.7b) $149.3m ($683.5m) ($301.9m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ($31.3m) ($18.6m) $400k $69.0m ($59.8m) ($55.7m) $35.1m ($67.7m) $101.9m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.3b $2.3b $3.4b $1.0b $2.4b $3.0b
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $281.2m $281.7m $243.2m $244.2m $272.7m $280.8m $262.5m $252.2m $245.4m $264.1m
Income Taxes Paid, Net $1.6b $1.1b $1.0b $1.1b $906.7m $247.9m $932.9m $740.7m $355.1m $864.0m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.